This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Regdanvimab parenteral


Parenteral formulations of regdanvimab.

Drugs List

  • regdanvimab 960mg/16ml concentrate for solution for infusion
  • REGKIRONA 960mg/16ml concentrate for solution for infusion
  • Therapeutic Indications


    Coronavirus disease 2019 (COVID-19) - treatment

    Treatment of adults with coronavirus 2019 (COVID-19) who do not require supplemental oxygen and who are at risk of progressing to severe COVID-19.


    The volume of regdanvimab is calculated as follows:

    Calculation to determine the total volume (ml) of regdanvimab to be administered
    Patient's body weight (kg) x regdanvimab dose (40mg/kg) divided by vial concentration (60mg/ml).

    Calculation to determine the total number of regdanvimab vials needed
    Total regdanvimab volume (ml) to be administered divided by total volume per vial (16ml/vial).


    Recommended single dose of 40mg/kg.

    Maximum recommended dose of 8g.


    For intravenous infusion only. Dilute and administer intravenously over 60 minutes


    Children under 18 years

    Precautions and Warnings


    Monitor patient throughout infusion and for at least 1 hour afterwards
    Concentrate must be diluted and used as an infusion
    If adverse reactions occur, reduce rate or temporarily stop infusion
    Record name and batch number of administered product
    Resuscitation facilities must be immediately available
    Monitor for hypersensitivity reactions during infusion
    Monitor patient for infusion-associated reactions (IARs)

    Pregnancy and Lactation


    Use regdanvimab with caution during pregnancy.

    The manufacturer does not recommend using regdanvimab unless the expected benefit to the mother justifies the potential risk to the foetus. A the time of writing there is limited published information regarding the use of regdanvimab during pregnancy. Potential risks are unknown. However, human immunoglobulin GI (IgGI) antibodies are known to cross the placental barrier; therefore regdanvimab has the potential to be transferred from the mother to developing foetus.


    Use regdanvimab with caution during breastfeeding.

    The manufacturer states the use of regdanvimab may be considered during breastfeeding when clinically indicated. The presence of regdanvimab in human breast milk and the effects on exposed infants are unknown.

    Side Effects

    Chest discomfort
    Infusion related reaction


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: January 2022

    Reference Sources

    Summary of Product Characteristics: Regkirona 60mg/ml concentrate for solution for infusion. Celltrion Healthcare Hungary Kft. Revised November 2021.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.